In addition, the FDA has orphan drug designation orphan drug designation ATIR as a cell-based therapy to reduce transplant mortality of graft versus host disease and / or infections caused by allogeneic bone marrow transplantation.
ATIR continue to show excellent clinical outcomes in patients receiving a non – mismatched bone marrow transplant from a family member donor. The two-year follow-up data from the Phase I / II study show no Transplant Mortality in a group of 10 high-risk leukemia patients who receive an effective dose of ATIR. The overall survival of this group after two years at 70 percent. These results compare favorably to the results of bone marrow transplantation from a fully matching donor.Is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug research, development and commercialization .
Long-term nonprogressors and elite controllers is rare individuals who are include HIV since many years, be without any sort of antiretroviral therapy. proposing Direct or indirect line of evidence in humans and animal models that virus -specific immune cells referred CD8+ T cells mediate this control. However, the mechanisms by which this occurs to stay unknown Date, says senior study author Dr. Mark Connors at in the National Institute Allergy and Infectious Diseases in Bethesda, Maryland.